PKC COMPLETES MANNEQUIN MODEL OF MAGNETIC BREATHER PUMP
Model Demonstrates All Functions of Smart Implantable Pump to Treat Brain Tumors

INGLEWOOD, CALIFORNIA, August 14, 2006 – Pharmaco-Kinesis Corporation (PKC), an advanced medical device company developing smart local drug delivery systems, today reported that the Company has scaled down the benchtop model of its Magnetic Breather Pump™ (MBP) to the size of a mannequin model for demonstration purposes.

“The mannequin model of our Magnetic Breather Pump allows us to demonstrate the many benefits of our smart implantable pump to industry and academic experts as we continue to miniaturize this potentially revolutionary device for the treatment of malignant gliomas and other aggressive brain tumors,” said Josh Shachar, Founder, Director and Chairman of the Scientific Advisory Board of Pharmaco-Kinesis. “We look forward to engaging in development activities to prove the significant potential benefits to cancer patients of the MBP and commercialize this product. These activities in turn are designed to maximize the shareholder value of our investments in this technology.”

“The MBP is expected to be the first implantable pump with a smart catheter for intratumoral drug delivery,” said Dr. Winston Wu, Ph.D., Director of Engineering at PKC. “This device can potentially eliminate repeated brain surgery procedures, reduce the cost and enhance the effectiveness of tumor fighting medications while also improving patient quality of life and increasing patient survival,” said Dr. Wu.

The MBP is designed to use advanced micro-fluidic, diagnostic and control mechanisms to deliver a variable, remotely programmable, metronomic combination of a plurality of tumor fighting medications within one implantable system. The MBP has four major subsystems: 1) an internalized pumping subsystem with reservoirs containing biological agents, capable of both delivering drugs at microliters/hour and sampling tumor fluids, 2) VEGF (Vascular Endothelial Growth Factor) detector providing feedback on treatment progress, 3) an implantable control system that processes signals from the VEGF detector and other sensors and issues commands to the pumping system, and 4) an intratumoral delivery catheter (for unresectable tumors) or an intracranial pouch (for the tumor cavity in resected tumors). The mannequin model contains these four components connected to demonstrate proof of principle in vitro.

The pumping systems, VEGF detector and control system will be miniaturized and housed within one unit secured at the chest wall. Multiple medication reservoirs within the MBP will be replenished through an injection apparatus. The reservoirs in the delivery pump may be accessed via subcutaneous ports to "refill" the drugs, and each reservoir can be wirelessly reprogrammed to deliver at specific time intervals and cycles. Energy will be provided to the MBP through a wireless charger system. The MBP is able to measure patient physical activity and position by means of a 3D accelerometer.

Advanced components of the MBP include a compact Optical BioSensor™ and an Organic Aptamer BioSensor ™ that provide real time measurement of a patient's VEGF levels in cerebrospinal or tumor fluid. The two proprietary devices are designed to provide a redundant measurement system that supports filings to regulatory authorities. Measurement of VEGF levels can indicate whether tumors are growing or shrinking. This and other information provided through the MBP measurement systems at the tumor site, such as temperature, pressure and pH, can be used to optimize treatment over time.

PKC is planning to conduct in vitro and in vivo testing of the MBP during the next 12 months. The Company is planning to complete the next stage of miniaturizing the MPB to the size of current implantable devices during the first half of 2010.

Under the leadership of Dr. Wu, the PKC R&D team is engaged in several product development programs for commercialization of novel smart local drug delivery technologies and advanced devices to measure biological responses.

“Winston and the development team at Pharmaco-Kinesis have reached an important milestone in scaling down the MBP into the mannequin model,” said Frank Adell, Founder, President and CEO of PKC. “We look forward to using this model to develop strategic partnerships as part of the commercialization program for the MBP.”

For additional information, please contact:
Daniel Saks Senior
Vice President, Corporate Affairs
Pharmaco-Kinesis Corporation
(310) 734-4447